Home » Stocks » Merus N.V.

Merus N.V. (MRUS)

Stock Price: $13.77 USD 0.00 (0.00%)
Updated Aug 3, 2020 4:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 399.90M
Revenue (ttm) 28.61M
Net Income (ttm) -64.83M
Shares Out 29.04M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $13.77
Previous Close $13.77
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 13.59 - 14.00
Day's Volume 0
52-Week Range 10.19 - 20.95

More Stats

Market Cap 399.90M
Enterprise Value 190.74M
Earnings Date (est) Aug 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.04M
Float 12.73M
EPS (basic) -2.663
EPS (diluted) -2.52
FCF / Share -2.65
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 258,299
Short Ratio 3.26
Short % of Float 1.18%
Beta 0.78
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 13.98
PB Ratio 3.50
Revenue 28.61M
Operating Income -68.76M
Net Income -64.83M
Free Cash Flow -76.82M
Net Cash 209.16M
Net Cash / Share 7.20
Gross Margin -85.81%
Operating Margin -240.36%
Profit Margin -223.80%
FCF Margin -268.55%
ROA -17.98%
ROE -60.86%
ROIC -171.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.48*
(56.00% upside)
Low
16.8
Current: $13.77
High
25.0
Target: 21.48
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue31.1338.3824.112.762.101.43
Revenue Growth-18.88%59.2%773.11%31.76%46.2%-
Gross Profit31.1338.3824.112.762.101.43
Operating Income-58.66-45.74-38.83-30.67-25.42-19.16
Net Income-55.15-28.31-71.25-52.18-25.58-19.15
Shares Outstanding24.2222.2916.0914.2414.24-
Earnings Per Share-2.28-1.27-3.71-3.94-4.36-6.77
Operating Cash Flow-63.05-46.10-41.08-28.31-25.12-16.00
Capital Expenditures-2.22-1.83-0.80-0.55-0.11-0.17
Free Cash Flow-65.27-47.93-41.87-28.85-25.23-16.18
Cash & Equivalents24023520275.6436.141.72
Total Debt5.252.69-0.530.720.90
Net Cash / Debt23523320275.1135.420.82
Assets26325321679.5439.043.89
Liabilities13214715441.687.917.81
Book Value13110662.2537.8631.13-3.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Merus N.V.
Country Netherlands
Employees 87
CEO Sven Ante Lundberg

Stock Information

Ticker Symbol MRUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MRUS
IPO Date May 19, 2016

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. Merus has collaboration with Caris Life Sciences to detect NRG1 fusions in cancer patients. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.